KLK3 and cancer: Additional liquid biopsy-based biomarkers are desirable to overcome the shortcomings of PSA in treatment monitoring of mPCA, and pan-cancer ccfDNA methylation markers mSEPT9 and mSHOX2 may provide a promising tool.